Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (141-150 of 186) with videos related to

Pageof 19
Sort By:
Public Health Genomics|September 28, 2016
Test Pricing and Reimbursement in Genomic Medicine: Towards a General StrategyAthanassios Vozikis, David N Cooper, Christina Mitropoulou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2011
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303Federico Innocenti, Kouros Owzar, Nancy L Cox, et al.
Nature Communications|September 18, 2022
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancerRadia M Johnson, Xueping Qu, Chu-Fang Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)Andrew B Nixon, Alexander B Sibley, Yingmiao Liu, et al.
Pharmacogenetics and Genomics|May 15, 2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751Federico Innocenti, Jacqueline Ramírez, Jennifer Obel, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
JAMA Oncology|September 17, 2020
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal CancerChristopher Mackintosh, Chen Yuan, Fang-Shu Ou, et al.
Scientific Reports|November 7, 2018
Genetic variation determines VEGF-A plasma levels in cancer patientsFederico Innocenti, Chen Jiang, Alexander B Sibley, et al.
JNCI Cancer Spectrum|April 8, 2020
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)Justin C Brown, Sui Zhang, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)Donna Niedzwiecki, Wendy L Frankel, Alan P Venook, et al.
Pageof 19

Showing results (141-150 of 186) with videos related to

Sort By:
Pageof 19
Public Health Genomics|September 28, 2016
Test Pricing and Reimbursement in Genomic Medicine: Towards a General StrategyAthanassios Vozikis, David N Cooper, Christina Mitropoulou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2011
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303Federico Innocenti, Kouros Owzar, Nancy L Cox, et al.
Nature Communications|September 18, 2022
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancerRadia M Johnson, Xueping Qu, Chu-Fang Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)Andrew B Nixon, Alexander B Sibley, Yingmiao Liu, et al.
Pharmacogenetics and Genomics|May 15, 2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751Federico Innocenti, Jacqueline Ramírez, Jennifer Obel, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
JAMA Oncology|September 17, 2020
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal CancerChristopher Mackintosh, Chen Yuan, Fang-Shu Ou, et al.
Scientific Reports|November 7, 2018
Genetic variation determines VEGF-A plasma levels in cancer patientsFederico Innocenti, Chen Jiang, Alexander B Sibley, et al.
JNCI Cancer Spectrum|April 8, 2020
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)Justin C Brown, Sui Zhang, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)Donna Niedzwiecki, Wendy L Frankel, Alan P Venook, et al.
Pageof 19